These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 27626781)

  • 1. Perspective: What next for treatment?
    Motzer RJ
    Nature; 2016 Sep; 537(7620):S111. PubMed ID: 27626781
    [No Abstract]   [Full Text] [Related]  

  • 2. Targeted therapy: An elusive cancer target.
    Brown C
    Nature; 2016 Sep; 537(7620):S106-8. PubMed ID: 27626779
    [No Abstract]   [Full Text] [Related]  

  • 3. Progress in the management of advanced renal cell carcinoma (RCC).
    Tong TQ; Rohde D; Peter S
    Aktuelle Urol; 2010 Jan; 41 Suppl 1():S57-60. PubMed ID: 20094957
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The silent disease.
    Shaw G
    Nature; 2016 Sep; 537(7620):S98-9. PubMed ID: 27626783
    [No Abstract]   [Full Text] [Related]  

  • 5. Anti-angiogenic therapy in renal cell carcinoma.
    Sharma SG; Nanda S; Longo S
    Recent Pat Anticancer Drug Discov; 2010 Jan; 5(1):77-83. PubMed ID: 19601920
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [VHL, angiogenesis and renal carcinoma: the puzzle is complete].
    Richard S
    Ann Pathol; 2000 Mar; 20(2):107-9. PubMed ID: 10740003
    [No Abstract]   [Full Text] [Related]  

  • 7. [The role of angiogenesis in renal carcinoma].
    Bussolati B; Satolli MA; Camussi G
    G Ital Nefrol; 2008; 25(3):297-305. PubMed ID: 18473301
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Resistance to sunitinib in renal cell carcinoma: From molecular mechanisms to predictive markers and future perspectives.
    Joosten SC; Hamming L; Soetekouw PM; Aarts MJ; Veeck J; van Engeland M; Tjan-Heijnen VC
    Biochim Biophys Acta; 2015 Jan; 1855(1):1-16. PubMed ID: 25446042
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Development of angiogenesis inhibitory combination therapies for treatment of renal cell carcinoma].
    Bartsch G; Eggert K; Soker S; Fiedler W; Laack E; Volkmer BG; Gschwend J; Bokemeyer C; Hautmann R; Schuch G
    Urologe A; 2007 Sep; 46(9):1289-90. PubMed ID: 17624513
    [No Abstract]   [Full Text] [Related]  

  • 10. Angiogenesis and angiogenic inhibitors in renal cell carcinoma.
    Sawhney R; Kabbinavar F
    Curr Urol Rep; 2008 Jan; 9(1):26-33. PubMed ID: 18366971
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Renal cell carcinoma: rationale and development of therapeutic inhibitors of angiogenesis.
    Ebbinghaus SW; Gordon MS
    Hematol Oncol Clin North Am; 2004 Oct; 18(5):1143-59, ix-x. PubMed ID: 15474339
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predicting outcome to VEGF-targeted therapy in metastatic clear-cell renal cell carcinoma: data from recent studies.
    Golshayan AR; Brick AJ; Choueiri TK
    Future Oncol; 2008 Feb; 4(1):85-92. PubMed ID: 18241003
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular markers to predict response to therapy.
    Garcia-Donas J; Rodriguez-Antona C; Jonasch E
    Semin Oncol; 2013 Aug; 40(4):444-58. PubMed ID: 23972708
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Suppression of mitochondrial respiration with auraptene inhibits the progression of renal cell carcinoma: involvement of HIF-1α degradation.
    Jang Y; Han J; Kim SJ; Kim J; Lee MJ; Jeong S; Ryu MJ; Seo KS; Choi SY; Shong M; Lim K; Heo JY; Kweon GR
    Oncotarget; 2015 Nov; 6(35):38127-38. PubMed ID: 26474388
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The von Hippel-Lindau protein, vascular endothelial growth factor, and kidney cancer.
    George DJ; Kaelin WG
    N Engl J Med; 2003 Jul; 349(5):419-21. PubMed ID: 12890838
    [No Abstract]   [Full Text] [Related]  

  • 16. VHL-gene deletion in single renal tubular epithelial cells and renal tubular cysts: further evidence for a cyst-dependent progression pathway of clear cell renal carcinoma in von Hippel-Lindau disease.
    Montani M; Heinimann K; von Teichman A; Rudolph T; Perren A; Moch H
    Am J Surg Pathol; 2010 Jun; 34(6):806-15. PubMed ID: 20431476
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting angiogenesis in metastatic renal cell carcinoma.
    Canino C; Perrone L; Bosco E; Saltalamacchia G; Mosca A; Rizzo M; Porta C
    Expert Rev Anticancer Ther; 2019 Mar; 19(3):245-257. PubMed ID: 30678509
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chromosomes, hypoxia, angiogenesis, and trial design: a brief history of renal cancer drug development.
    Stadler W
    Clin Cancer Res; 2007 Mar; 13(6):1630-3. PubMed ID: 17363513
    [No Abstract]   [Full Text] [Related]  

  • 19. Renal-cell carcinoma--molecular pathways and therapies.
    Brugarolas J
    N Engl J Med; 2007 Jan; 356(2):185-7. PubMed ID: 17215538
    [No Abstract]   [Full Text] [Related]  

  • 20. Target-specific therapy requires target-specific populations in the treatment of renal cell carcinoma.
    Figlin RA; Alvin H; Meinhardt CL
    Urologe A; 2004 Sep; 43 Suppl 3():S144-5. PubMed ID: 15179554
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.